More information about text formats
To address the concern of potential cross-reactivity of SARS-CoV-2 with Architect HIV Combo assay (Abbott Laboratories, Abbott Park, Illinois, USA) reported in this article, we evaluated 846 COVID-19 convalescent plasma samples obtained from New York Blood Center (New York, New York, USA) using the Architect HIV Combo assay. Although all 846 samples were reactive in Architect SARS-Cov-2 IgG assay (Abbott Laboratories, Abbott Park, Illinois, USA), none of the samples were reactive in the Architect HIV Combo assay with average signal < 0.14 S/CO and standard deviation < 0.058 S/CO. Thus, the data shows no indication of cross-reactivity between SARS-CoV-2 infection and Architect HIV Combo assay.
Furthermore, it is well known that HIV-1 gp41 protein also shows striking structural similarity to the fusion pH-induced conformation of influenza virus HA2 protein (Weissenhorn et. al. Nature 1997, 387:426). However, to our knowledge, no cross-reactivity case from flu vaccinated samples has been reported with the Architect HIV Combo assay since its launch in 2004. Collectively, the cross-reactivity of SARS-CoV-2 infection with Architect HIV Combo assay should be extremely low.